Neuroendocrine malignancy of the larynx are rare but represents the first nonsquamous tumor in this localization. The World Health Organization (WHO) classifies these tumors into 3 groups: typical carcinoid, atypical carcinoid tumor, and small cell neuroendocrine carcinoma (SmCC). SmCC have an aggressive natural history characterized by widespread metastasis. Treatment is based on concomitant or sequential chemoradiation. We report herein the case of a 69 years old men, who presented with laryngeal small cell neuroendocrine carcinoma revealed by progressive dysphonia and cervical lymphadenopathy. The diagnosis was confirmed by biopsy and histopathological study. Pre-treatment workup was negative for metastatic disease. He has received chemotherapy based on etoposide and cisplatin followed by chemoradiation. The evolution was marked by the development of metachronous lung metastasis. Unfortunately, the patient passed away during a chemotherapy-induced myelosuppression after the first palliative chemotherapy cure.
No takes yet. Share an insight, caveat, or question.
Laatitioui et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: